BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed riboswitches – an innovative class of RNA drug targets found in pathogenic bacteria and fungi.
KALEXSYN CEO David Zimmermann said the company has been a key collaborator on medicinal chemistry strategy and has provided high impact synthetic expertise to BioRelix for several years.
BioRelix CEO Brian Dixon said they chose to work with KALEXSYN because of their expertise and their ability to fully engage in the scientific discovery process with their research team.